NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 11.53 against a street estimate of 8.04 — a beat of 43.4%.
with an average price target of ₹1,004.44.
MIXED Q1 FY'27 revenue fell 43% YoY to INR 794 crores due to lower lenalidomide, offset by 24% PAT growth and strong Brazil (98% growth). Adcock stake raised to 49%; INR 2,000 crore fundraise planned for acquisitions. Q1 FY'27 Brazil driving strongest export growth (98% YoY); Brazil and Canada identified as primary expansion geographies alongside U.S. launches. India domestic base stable with oncology strength. South Africa now strategic with 49% Adcock holding. Analysts pressed on seasonality vs structural decline (Q1 trough, but Adcock profit not repeatable). Management emphasized cyclical order patterns and explained fundraise rationale as investment in M&A, not balance sheet weakness. Litigation on ola tariff and semaglutide profitability emerged as key near-term risks; timelines remain uncertain. 2026-08-14…
Full summary in the app.
| Document | Date |
|---|---|
| Annual report FY2026 NATCO PHARMA LIMITED – FY 2025-26 SUMMARY HEADLINE NUMBERS • Revenue from operations: ₹40,783 million (FY 2024-25: ₹44,295 million) – declined 7.9% | 2026-09-04 |
| Investor presentation · Q1 FY27 NATCO PHARMA LIMITED – INVESTOR PRESENTATION SUMMARY August 2026 --- HEADLINE NUMBERS • Global revenues FY26: INR 43,759 Million ($495 Million at a | 2026-08-19 |
| Q1 FY27 earnings call NATCO PHARMA LIMITED – Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Consolidated total revenues: INR 794.4 crores (Q1 FY27) vs INR 1,390.6 crores (Q1 | 2026-08-18 |
| Quarterly results · Q1 FY27 NATCO PHARMA LIMITED – Q1 FY27 RESULTS SUMMARY HEADLINE NUMBERS • Consolidated total revenue: ₹794.4 Crore for Q1 FY27 (ended 30th June 2026), down | 2026-08-14 |
| Q4 FY26 earnings call NATCO PHARMA LIMITED – Q4 FY'26 EARNINGS SUMMARY HEADLINE NUMBERS • Full year FY26 consolidated revenue: INR 4,375.9 crores (down from INR 4,784 cro | 2026-06-04 |
| Investor presentation · Q4 FY26 NATCO PHARMA LIMITED – Q4FY26 & FY26 SUMMARY HEADLINE NUMBERS • FY26 Total Revenue: INR 43,759 Mn (down from INR 47,840 Mn in FY25) • FY26 EBITDA: I | 2026-05-29 |
| Quarterly results · Q4 FY26 NATCO PHARMA LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue from operations (Year ended 31-Mar-2026): ₹40,783 million (down from ₹44,295 mil | 2026-05-29 |
| Q3 FY26 earnings call NATCO PHARMA LIMITED – Q3 FY'26 EARNINGS SUMMARY HEADLINE NUMBERS • Q3 FY'26 Consolidated Total Revenue: INR 705.4 crores (vs INR 651.1 crores in Q3 | 2026-02-18 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1.50 / share ex-date Aug 20, 2026 | 2026-08-20 |
| Dividend | ₹1.50 / share ex-date Feb 18, 2026 | 2026-02-18 |
| Dividend | ₹1.50 / share ex-date Nov 20, 2025 | 2025-11-20 |
| Dividend | ₹2 / share ex-date Aug 19, 2025 | 2025-08-19 |
| Announcement | Date |
|---|---|
| Completes acquisition of additional 13.25% stake in Adcock Ingram NATCO Pharma Limited, an Indian pharmaceutical company, has completed the acquisition of an additional 13.25% stake in Adcock Ingram Holdings Proprietary Limited, a South African pharmaceuti | 2026-07-14 |
| Acquires 35.75% stake in Adcock Ingram Holdings Limited Natco Pharma Limited has acquired a 35.75% stake in Adcock Ingram Holdings Limited, a South African pharmaceutical company that has just completed its delisting from the Johannesburg Stock E | 2025-11-12 |
| Updates on proposed acquisition of shares in Adcock Ingram Holdings Natco Pharma Limited announced plans to acquire shares in Adcock Ingram Holdings Limited, a South African pharmaceutical company. This acquisition represents a strategic expansion move for N | 2025-10-10 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Natco Pharma Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.